Principal Financial Group Inc. Has $3.23 Million Holdings in STAAR Surgical Company (STAA)
Principal Financial Group Inc. raised its stake in STAAR Surgical Company (NASDAQ:STAA) by 1.2% during the second quarter, according to its most recent filing with the Securities and Exchange Commission. The fund owned 298,723 shares of the medical instruments supplier’s stock after buying an additional 3,594 shares during the period. Principal Financial Group Inc. owned about 0.73% of STAAR Surgical worth $3,226,000 as of its most recent SEC filing.
Other hedge funds and other institutional investors also recently added to or reduced their stakes in the company. Goldman Sachs Group Inc. bought a new stake in shares of STAAR Surgical in the 1st quarter valued at about $111,000. Simplex Trading LLC grew its position in shares of STAAR Surgical by 1,798.8% in the 2nd quarter. Simplex Trading LLC now owns 12,779 shares of the medical instruments supplier’s stock valued at $138,000 after buying an additional 12,106 shares during the last quarter. Bristol Advisors LLC bought a new stake in shares of STAAR Surgical in the 2nd quarter valued at about $216,000. Trexquant Investment LP grew its position in shares of STAAR Surgical by 30.8% in the 1st quarter. Trexquant Investment LP now owns 22,105 shares of the medical instruments supplier’s stock valued at $217,000 after buying an additional 5,205 shares during the last quarter. Finally, American International Group Inc. grew its position in shares of STAAR Surgical by 7.1% in the 1st quarter. American International Group Inc. now owns 24,648 shares of the medical instruments supplier’s stock valued at $242,000 after buying an additional 1,631 shares during the last quarter. Hedge funds and other institutional investors own 76.54% of the company’s stock.
COPYRIGHT VIOLATION WARNING: This report was first reported by The Cerbat Gem and is the sole property of of The Cerbat Gem. If you are reading this report on another publication, it was illegally copied and reposted in violation of United States and international copyright laws. The original version of this report can be viewed at https://www.thecerbatgem.com/2017/10/06/principal-financial-group-inc-has-3-23-million-holdings-in-staar-surgical-company-staa.html.
A number of equities research analysts have commented on STAA shares. TheStreet upgraded STAAR Surgical from a “d+” rating to a “c” rating in a research report on Tuesday, August 15th. Canaccord Genuity upped their target price on STAAR Surgical from $9.00 to $11.00 and gave the company a “hold” rating in a research report on Thursday, August 3rd. Benchmark Co. upped their target price on STAAR Surgical from $12.00 to $13.00 and gave the company a “buy” rating in a research report on Monday, August 14th. Zacks Investment Research lowered STAAR Surgical from a “buy” rating to a “hold” rating in a research report on Friday, September 22nd. Finally, BidaskClub upgraded STAAR Surgical from a “sell” rating to a “hold” rating in a research report on Saturday, August 19th. One analyst has rated the stock with a hold rating and three have issued a buy rating to the company’s stock. STAAR Surgical presently has an average rating of “Buy” and an average target price of $13.33.
Shares of STAAR Surgical Company (NASDAQ:STAA) opened at 13.75 on Friday. STAAR Surgical Company has a 12 month low of $7.45 and a 12 month high of $13.90. The company’s market cap is $565.24 million. The company’s 50 day moving average price is $11.96 and its 200 day moving average price is $10.49.
STAAR Surgical (NASDAQ:STAA) last posted its earnings results on Wednesday, August 2nd. The medical instruments supplier reported ($0.01) earnings per share (EPS) for the quarter, topping the Thomson Reuters’ consensus estimate of ($0.05) by $0.04. The company had revenue of $21.90 million for the quarter, compared to analysts’ expectations of $22.15 million. STAAR Surgical had a negative return on equity of 8.69% and a negative net margin of 6.06%. STAAR Surgical’s quarterly revenue was up 4.8% on a year-over-year basis. During the same period last year, the firm earned ($0.02) earnings per share. On average, equities analysts expect that STAAR Surgical Company will post ($0.11) EPS for the current fiscal year.
About STAAR Surgical
STAAR Surgical Company designs, develops, manufactures and sells implantable lenses for the eye and delivery systems used to deliver the lenses into the eye. It operates in the ophthalmic surgical market segment. Its principal products are intraocular lenses used in cataract surgery and implantable collamer lenses used in refractive surgery.
Receive News & Stock Ratings for STAAR Surgical Company Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for STAAR Surgical Company and related stocks with our FREE daily email newsletter.